U.S. API buyers often ask a simple question before sourcing tadalafil: is tadalafil a controlled substance? The short answer is no. Tadalafil is not listed in the DEA’s current alphabetical controlled-substance list, and DailyMed labels for finished tadalafil tablets identify the product as prescription-only rather than federally scheduled. That distinction matters for procurement. “Not controlled” does not mean Tadalafil API can be imported, sampled or distributed without FDA, customs, quality and supplier-document review. This guide explains Tadalafil API controlled substance status in the USA, what it does not change, and the verification points that matter before a quote or supplier approval.
Is Tadalafil a Controlled Substance in the United States?
Tadalafil is not listed as a DEA-scheduled controlled substance in the DEA Diversion Control Division’s current alphabetical controlled-substance list. That supports the core status answer: tadalafil is not federally scheduled as a controlled substance under the U.S. Controlled Substances Act.
DailyMed labels for finished tadalafil tablets also show why buyers must keep the categories separate. They identify finished tadalafil tablets as human prescription drug products with NDC, ANDA, labeler, registrant and establishment information. For a buyer, that means tadalafil should not be treated as a Schedule I, II, III, IV or V controlled substance merely because it is prescription-only.
The absence of a DEA schedule for tadalafil does not convert Tadalafil API into an unrestricted commodity. It only answers one regulatory question. FDA, customs, product-quality and destination-market requirements still have to be reviewed for the exact product route.
Why Prescription-Only Still Matters for Finished Tadalafil
The same DailyMed label makes clear that Cialis is a prescription medicine used under a healthcare provider’s care. In B2B procurement, that prescription status translates into product-route review before a quote can be treated as commercially usable.
A finished tadalafil tablet intended for U.S. commercial distribution raises questions about application status, NDC/listing data, label, pack, authorization, distributor role and supply-chain traceability. A tadalafil API intended for formulation, development, testing or dossier work raises different questions about API grade, manufacturer identity, cGMP evidence, COA, SDS, specification, impurity profile, DMF or other regulatory support and intended use.
Tadalafil: Controlled Substance vs Prescription Drug
The common mistake is treating “prescription-only” and “controlled substance” as the same category. They are different regulatory concepts.
A controlled substance is subject to DEA scheduling and additional controls because of abuse, dependence or diversion risk. A prescription drug, by contrast, may require FDA oversight, medical supervision and lawful dispensing controls even if it is not DEA-scheduled.
This distinction matters in sourcing discussions. A supplier saying “not controlled” may be answering only one narrow question. The buyer still needs to ask whether the quoted product is an API or finished dosage form, whether it has a lawful U.S. route, whether the foreign establishment and product listing are aligned, and whether the supplier can provide documents that match the legal manufacturer and shipment.
Can Tadalafil API Be Imported Into the U.S. if It Is Not Controlled?
No. FDA’s API import guidance explains that APIs imported or offered for import into the United States are subject to applicable FD&C Act and 21 CFR requirements. FDA also states that foreign establishments manufacturing APIs for U.S. import generally have establishment-registration obligations, with some exceptions based on activity and supply route.
FDA’s human-drug import guidance explains that entry reviewers may verify information such as the declared manufacturer, declared importer or consignee, product description, Affirmations of Compliance codes and intended use code. If the entry data does not match FDA systems or expected documentation, the shipment may be delayed, detained or refused.
That is the practical point for Tadalafil API buyers: non-scheduled status can reduce one DEA-specific concern, but it does not replace the FDA import and product-quality review file.
What Non-Controlled Status Means for Tadalafil API and Finished Tablets
For Tadalafil API sourcing, “not controlled” may simplify some DEA-specific questions, but the buyer still needs to verify product identity and intended use. Important API checks include:
- API name, CAS number, grade and pharmacopeial reference.
- Legal manufacturer and manufacturing-site identity.
- COA, specification, SDS, residual solvents and impurity profile.
- GMP evidence tied to the correct site and activity.
- DMF, CEP, ASMF, letter of authorization or other support where relevant.
- Sample availability, retest period, storage condition and export packaging.
- Destination-country import requirements and buyer authority.
For finished tadalafil tablets, the evidence file is different. U.S.-focused review covers whether the exact product, strength, pack, labeler, manufacturer and distribution route are acceptable. Finished-dose review may include NDA or ANDA pathway evidence, NDC/listing data, label and artwork, batch COA, stability data, packaging configuration, serialization or traceability requirements, distributor authorization and any DSCSA-relevant transaction evidence.
Buyers comparing API and finished-dose routes can use Pharmint’s USA tadalafil procurement checklist for route planning and Pharmint’s Tadalafil API documentation guide for document interpretation.
Does a Tadalafil API Supplier Need DEA Registration?
A blanket yes-or-no answer is not reliable for every transaction. If the activity involves only non-scheduled Tadalafil API, the first DEA question is different from the question that would apply to a Schedule I-V controlled substance. But the supplier, importer, distributor, manufacturer, broker or lab may still have FDA, customs, state, licensing, quality-system, registration, listing, import-entry or destination-market obligations based on the exact role and product route.
A cleaner procurement screen separates two questions: whether the product or any ingredient in the shipment is federally controlled, and what FDA, import, establishment, buyer-license and documentation obligations apply to the specific Tadalafil API transaction. Regulatory, legal and customs teams normally confirm those obligations before supplier or shipment approval.
Tadalafil API Procurement Risks for U.S. Buyers
The biggest risk is a false shortcut: “not controlled” becomes “easy to import.” That is wrong. FDA import expectations, customs data, product approval status, labeling and cGMP evidence still matter.
A second risk is mixing tadalafil with other ingredients or hidden-drug products. FDA’s May 29, 2026 notice for Erectus Plus reported undeclared sildenafil, tadalafil and testosterone propionate. The same FDA notice identified testosterone propionate as a controlled substance. A sexual wellness product may not have the same status as pure tadalafil API or a lawful tadalafil finished tablet. Each ingredient, claim, label and formulation route needs separate review.
A third risk is counterfeit or unauthorized Cialis-like supply. FDA has warned about counterfeit Cialis tablets identified entering the United States and noted red flags such as missing NDC information, label differences and misspellings. That warning is consumer-facing, but the B2B implication is direct: product authenticity, NDC/listing alignment, lawful channel evidence and supplier authorization belong in the review before price comparison.
Tadalafil API Sourcing Checklist for US Buyers
A useful Tadalafil API RFQ makes the product route explicit and includes:
- Product route: Tadalafil API, finished tablet, repackaged product, combination product, sample or development material.
- Destination and use: U.S. commercial distribution, formulation, testing, dossier work, import-for-export or another lawful route.
- Buyer role: importer, distributor, wholesaler, manufacturer, CDMO, lab, institution or procurement agent.
- Quantity, pack and strength: API quantity, tablet strength, pack configuration and required timeline.
- Documentation: COA, SDS, specification, GMP evidence, DMF/LOA support, label, NDC/listing, application or authorization evidence where applicable.
- Supplier identity: seller, legal manufacturer, manufacturing site, labeler, exporter and any broker or trader role.
- Shipment data: country of origin, HS code, Incoterm, declared manufacturer, importer/consignee, intended use code and A of C support where applicable.
- Review responsibilities: buyer QA, RA, legal, customs broker and receiving-release plan.
If the supplier cannot answer these questions, the controlled-substance answer is not enough to approve the transaction.
Source Tadalafil API With the Required Documentation
Pharmint helps qualified B2B buyers move from a vague tadalafil sourcing question to a structured RFQ. Buyers can define whether they need Tadalafil API, finished tablets or a related product route, then request supplier options with document expectations, destination requirements and timeline clearly stated.
For API-focused sourcing, start with Pharmint’s USA tadalafil procurement checklist, then review the Tadalafil API documentation guide and the guide on how to verify a Tadalafil API supplier. Buyers ready to map supplier options can also review Pharmint’s Tadalafil suppliers page before moving to the Tadalafil API product page.
Pharmint does not replace the buyer’s regulatory counsel, quality unit, customs broker, legal team, pharmacist, responsible person or destination regulator. Final supplier approval, product acceptance, import admissibility, distribution authority and batch release remain the buyer’s responsibility.
If your organization is ready to compare documented options, request a structured Tadalafil quote with your product route, quantity, destination, buyer role, intended use, document requirements and target timeline.
Tadalafil Controlled Substance FAQs
Is tadalafil a controlled substance in the U.S.?
No. The DEA’s current alphabetical controlled-substance list does not list tadalafil. Finished tadalafil products are still prescription medicines, so buyers should not treat tadalafil as an unrestricted consumer product.
Is Cialis a controlled substance?
No. Cialis contains tadalafil and is handled as a prescription drug, not as a federally scheduled controlled substance. Buyers should still verify the exact product, label, NDC/listing and lawful distribution route.
Does “not controlled” mean Tadalafil API can be imported freely?
No. Non-controlled status does not remove FDA API import requirements. U.S. buyers still need to review the product route, manufacturer registration, listing, intended use, labeling, cGMP, entry data and documentation where applicable.
Does a Tadalafil API supplier need DEA registration?
Do not rely on a blanket answer. If the product is non-scheduled Tadalafil API, DEA controlled-substance registration may not be the central requirement, but the buyer still needs to confirm FDA, customs, state, licensing and transaction-specific obligations for the exact activity.
What should U.S. buyers ask for before sourcing Tadalafil API?
Buyers should request the legal manufacturer and site identity, COA, specification, SDS, GMP evidence, impurity and residual-solvent information, retest or stability data, packaging details and regulatory-support documents such as DMF, CEP or LOA where relevant.
What extra checks apply to finished tadalafil tablets?
Finished tablets require review of the exact product, strength, pack, label, NDC/listing, application or authorization pathway, manufacturer, labeler, distributor authority, traceability records and destination-market requirements.
Can Pharmint help compare tadalafil suppliers?
Pharmint can help qualified buyers structure sourcing requirements and compare supplier-document responses. Final regulatory, quality, legal, customs and batch-release decisions remain with the buyer’s authorized teams.
Sources and Regulatory References
- DEA Diversion Control Division: Controlled Substances – Alphabetical Order
- DailyMed: Tadalafil tablet, film coated label
- FDA: Importing Active Pharmaceutical Ingredients
- FDA: Importing Prescription Drugs
- FDA: Importing Human Drugs
- FDA: Counterfeit Versions of Cialis tablets identified entering the United States
- FDA: Erectus Plus may be harmful due to hidden drug ingredients
